Sanofi India receives marketing authorization for RSV vaccine Beyfortus from CDSCO.

Sanofi India gains marketing authorization for RSV vaccine, Beyfortus, preventing lower respiratory tract disease in newborns, infants, and children up to 24 months. The vaccine contains monoclonal antibody nirsevimab, approved by CDSCO on June 10, 2024. Beyfortus has already received approvals in the EU, US, China, and Japan.

August 01, 2024
3 Articles